REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Clinefnorte CIA Ltda (Ecuador)

Main Activities: General Medical and Surgical Hospitals
Full name: Clinefnorte CIA Ltda Profile Updated: April 12, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Spanish Download a sample report

Clinefnorte CIA Ltda is a company that specializes in renal replacement therapies, including hemodialysis, peritoneal dialysis, and renal transplants. They offer clinical care and use technology for their therapies. The company is committed to providing treatment for patients with kidney disease, including nutritional assistance. They also provide training for patients and caregivers to ensure therapy development.

Headquarters
Quitumbe N61-67, Casa Bldg.
Quito; Pichincha;

Contact Details: Purchase the Clinefnorte CIA Ltda report to view the information.

Website: https://clinefnorte.com/

Basic Information
Total Employees:
Purchase the Clinefnorte CIA Ltda report to view the information.
Outstanding Shares:
Purchase the Clinefnorte CIA Ltda report to view the information.
Registered Capital:
Purchase the Clinefnorte CIA Ltda report to view the information.
Incorporation Date:
July 08, 2005
Key Executives
Purchase this report to view the information.
President
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
50%
Purchase this report to view the information.
25%
Purchase this report to view the information.
25%
Company Performance
Financial values in the chart are available after Clinefnorte CIA Ltda report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
Net sales revenue
20.09%▲
Total operating revenue
20.09%▲
Operating profit (EBIT)
11816.19%▲
Net Profit (Loss) for the Period
15.52%▲
Total assets
40.43%▲
Total equity
26.78%▲
Operating Profit Margin (ROS)
27.16%▲
Net Profit Margin
-0.68%▼
Return on Equity (ROE)
-2.75%▼
Quick Ratio
-0.64%▼
Cash Ratio
-0.43%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo